The American Medical Association recognized obesity as a disease in 2013, sparking a rise in the popularity of injectable weight loss medications like semaglutide and tirzepatide. However, concerns about fatphobia and weight stigma have also increased with the use of these medications. Experts argue that it is important to consider various factors, such as body composition, metabolic health, and underlying medical conditions when prescribing these medications. Addressing weight bias and openly discussing the potential influence of fatphobia in decision making is essential. Moreover, a multidisciplinary approach to weight management, including support from dietitians, exercise specialists, and mental health providers, is crucial for the success of patients.
Source link
The Ozempic Aesthetic: Can Anti-Obesity Medications Cause More Harm Than Good?
